Salignostics Develops Breakthrough Saliva-Based HIV Test with High Accuracy in Ethiopian Clinical Trial

Medical diagnostics company Salignostics has achieved a significant milestone in HIV testing technology through a successful clinical trial in Ethiopia, showcasing a revolutionary saliva-based rapid test with exceptional diagnostic capabilities.

The clinical trial, conducted in November 2024, evaluated 100 saliva samples from both HIV-diagnosed and healthy participants. The results revealed remarkable accuracy, with the test demonstrating sensitivity exceeding 90% and specificity surpassing 98%. These findings represent a potential breakthrough in HIV diagnostic methodologies, particularly for regions with limited healthcare infrastructure.

The innovative test addresses critical challenges in HIV detection by eliminating the need for blood draws and specialized medical equipment. This non-invasive approach offers a cost-effective solution that can be deployed in diverse settings, including homes, community health centers, and rural clinics, potentially expanding access to critical diagnostic services.

The global HIV diagnostics market underscores the significance of this development. Projections indicate the market will grow to $7 billion by 2034, with a compound annual growth rate of 7.5%. Salignostics' technology could play a pivotal role in meeting the increasing demand for decentralized and user-friendly diagnostic solutions.

Dr. Guy Krief, Co-founder and Deputy CEO of Salignostics, emphasized the test's potential to complement existing HIV testing methods. The technology aims to provide a reliable and accessible diagnostic tool that can empower individuals in diverse communities to take control of their health with greater privacy and convenience.

Beyond this breakthrough, Salignostics has demonstrated expertise in saliva-based diagnostics, with its Salistick pregnancy test already achieving over 500,000 units sold across markets like the UK and Israel. The company holds CE, UKCA, and TGA certifications, and is expanding its diagnostic portfolio to include potential applications in oral cancer, respiratory conditions, and sexually transmitted infections.

The successful Ethiopian trial represents more than a technological achievement; it signifies a potential transformation in global healthcare accessibility. By developing an accurate, non-invasive HIV test, Salignostics is addressing critical gaps in public health diagnostics, particularly in regions with limited medical resources.